Cullinan Therapeutics, Inc. (CGEM) Earnings History
Annual and quarterly earnings data from 2018 to 2025
Loading earnings history...
CGEM EPS Growth (CAGR)
Compound annual growth rate of diluted earnings per share
CAGR (Compound Annual Growth Rate) shows the annualized growth rate of EPS over the specified period. A higher CAGR indicates stronger earnings momentum.
CGEM Profitability Analysis
Margin trends over time
| Year | Gross Margin | Operating Margin | Net Margin |
|---|---|---|---|
| 2025 | - | - | - |
| 2024 | - | - | - |
| 2023 | - | - | - |
| 2022 | - | - | - |
| 2021 | 100.0% | -358.7% | -346.1% |
Download Data
Export CGEM earnings history in CSV or JSON format
Free sign-in required to download data
Cullinan Therapeutics, Inc. (CGEM) Earnings Overview
As of May 8, 2026, Cullinan Therapeutics, Inc. (CGEM) reported trailing twelve-month net income of -$221M, reflecting -19.6% year-over-year growth. The company earned $-3.72 per diluted share over the past four quarters.
Looking at the long-term picture, CGEM's historical earnings data spans multiple years. The company achieved its highest annual net income of $111M in fiscal 2022.
Cullinan Therapeutics, Inc. is currently reporting a net loss, though operating performance should be evaluated in the context of growth investments and industry dynamics View revenue history →
Compared to peers including IMVT (-$464M net income), KYMR (-$315M net income, -794.4% margin), RCUS (-$369M net income, -142.9% margin), CGEM has comparable earnings metrics. Compare CGEM vs IMVT →
CGEM Earnings vs Peers
Earnings metrics vs comparable public companies
CGEM Historical Earnings Data (2018–2025)
8 years| Fiscal Year | Net Income | YoY % | Operating Income | EPS (Diluted) | Net Margin | Op. Margin |
|---|---|---|---|---|---|---|
| 2025 | -$220M | -31.4% | -$242M | $-3.72 | - | - |
| 2024 | -$167M | -9.3% | -$197M | $-3.11 | - | - |
| 2023 | -$153M | -237.7% | -$191M | $-3.69 | - | - |
| 2022 | $111M | +269.6% | $145M | $2.38 | - | - |
| 2021 | -$66M | -26.6% | -$68M | $-1.48 | -346.1% | -358.7% |
| 2020 | -$52M | -158.5% | -$60M | $-1.19 | - | - |
| 2019 | -$20M | -41.2% | -$22M | $-19.68 | - | - |
| 2018 | -$14M | - | -$15M | $-17.74 | - | - |
See CGEM's True Return
Price is only half the story. See total return with reinvested dividends.
Launch CalculatorIs CGEM Undervalued?
DCF intrinsic value, peer multiples, and analyst estimates — see what the stock is really worth.
View ValuationCompare CGEM vs DBVT
Side-by-side business, growth, and profitability comparison vs DBV Technologies S.A..
Start ComparisonCGEM — Frequently Asked Questions
Quick answers to the most common questions about buying CGEM stock.
Is CGEM growing earnings?
CGEM EPS fell to $-3.72, with earnings declining -19.6%. This contrasts with the 5-year CAGR of N/A. TTM net income dropped to $-221M.
What are CGEM's profit margins?
Cullinan Therapeutics, Inc. net margin is N/A, with operating margin at N/A. Below-average margins reflect competitive or cost pressures.
How consistent are CGEM's earnings?
CGEM earnings data spans 2018-2025. The declining earnings trend is -19.6% YoY. Historical data enables comparison across business cycles.